Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples